CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea
· Delayed Price · Currency is KRW
3,985.00
+125.00 (3.24%)
At close: Apr 28, 2026
KOSDAQ:261780 Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 104,640 | 75,894 | 82,084 | 151,036 | 131,749 | 293,364 | |
| Market Cap Growth | 44.21% | -7.54% | -45.65% | 14.64% | -55.09% | - | |
| Enterprise Value | 89,809 | 55,705 | 53,558 | 123,500 | 97,133 | 290,192 | |
| Last Close Price | 3895.00 | 2825.00 | 3060.00 | 5650.00 | 4985.00 | 11100.00 | |
| PS Ratio | 659.71 | 478.48 | 221.45 | 513.51 | 734.04 | 586.73 | |
| PB Ratio | 8.82 | 6.40 | 2.96 | 4.26 | 3.95 | 7.41 | |
| P/TBV Ratio | 9.00 | 6.53 | 2.98 | 4.27 | 3.95 | 7.41 | |
| EV/Sales Ratio | - | 351.19 | 144.49 | 419.89 | 541.18 | 580.38 | |
| Debt / Equity Ratio | 0.75 | 0.75 | 0.35 | 0.12 | 0.71 | 0.53 | |
| Net Debt / Equity Ratio | -1.25 | -1.25 | -1.10 | -0.98 | -1.02 | -1.03 | |
| Net Debt / EBITDA Ratio | 1.07 | 1.07 | 4.24 | 5.87 | 5.64 | 6.97 | |
| Net Debt / FCF Ratio | 1.33 | 1.33 | 3.69 | 6.20 | 6.06 | 7.51 | |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | |
| Quick Ratio | 1.49 | 1.49 | 4.21 | 48.57 | 2.18 | 2.50 | |
| Current Ratio | 1.66 | 1.66 | 4.64 | 52.44 | 2.20 | 2.50 | |
| Return on Equity (ROE) | -81.07% | -81.07% | -32.11% | -5.09% | -18.40% | -89.44% | |
| Return on Assets (ROA) | -23.16% | -23.16% | -10.42% | -7.56% | -6.40% | -8.35% | |
| Return on Capital Employed (ROCE) | -105.00% | -105.00% | -20.50% | -14.50% | -18.90% | -15.00% | |
| Earnings Yield | -15.33% | -21.14% | -12.35% | -1.16% | -5.10% | -6.28% | |
| FCF Yield | -10.64% | -14.67% | -10.08% | -3.69% | -4.28% | -1.85% | |
| Buyback Yield / Dilution | -0.20% | -0.20% | -0.76% | -0.69% | -13.39% | -30.03% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.